Article
Beta: A Powerful But Faulty Tool For Managing Risk
Beta: A Powerful But Faulty Tool For Managing Risk
Authored by Michael Lebowitz via RealInvestmentAdvice.com,
When investors want to reduce risk, one commonly used tool is beta. For instance, an investor may sell higher-beta stocks and replace them with lower-beta ones to cushion against an expected market decline. Such a strategy is intuitive and widely used; however, it can be greatly flawed.
We recently received a question from a client about how we use beta to manage our portfolios. Given recent volatility and declining prices, the timing could not be better to...
aboutLiberty Portal
Liberty Portal is your gateway for free markets and free thinking. We aggregate open-sourced content to promote and popularize important people and lessons within the liberty movement.
suggested
May 13, 2026 / Tyler Durden
Ugly, Tailing 30Y Auction Makes History With First 5%+ Yield Since The Great Quant Crash Of Aug 2007
Ugly, Tailing 30Y Auction Makes History With First 5%+ Yield Since The Great Quant Crash Of Aug 2007
Moments ago, the last refunding auction of the week, the sale of $25BN in 30Y paper, made history: it was the first 30Y auction to print with a high yield above 5%, and a coupon of 5%, since August 2007... which as veteran traders will recall was the month of the historic quant crash which marked the S&P highs at the time and eventually culminated in the global financial crisis.
The auction priced...
Read more
Apr 27, 2026 / Kyle Anzalone
German Chancellor Merz: Iran Is Humiliating the US
German Chancellor Friedrich Merz said that Iran has humiliated the US during the negotiating process. The US and Iran have held a round of talks and exchanged messages through Pakistan, but have been unable to reach an agreement. “The Iranians are obviously very skilled at negotiating, or rather, very skilful at not negotiating, letting the […]
Read more
Apr 6, 2026 / Tyler Durden
Big Pharma Forced To Yank COVID Vaxx Study Due To Lack Of Participants
Big Pharma Forced To Yank COVID Vaxx Study Due To Lack Of Participants
Authored by Ben Sellers via Headline USA,
Two of the major pharmaceutical companies connected with the controversial COVID vaccines were forced to abandon a new research study after failing to garner enough participants.
Pfizer and German vax maker BioNTech had sought to research an updated version of the vaccine in adults ages 50 to 64, but were unable to generate the data needed due to the low enrollment in the trials, Reuters reported.
The study was needed in order to meet new guidelines imposed by the Food and Drug Administration that...
Read more




